Latanoprost detailed information

Latanoprost detailed information

Clinical data
Routes of administration	Topical (eye drops)
ATC code	S01EE01 (WHO)
Pharmacokinetic data
Elimination half-life	17 minutes
Identifiers
IUPAC name propan-2-yl 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pentyl) -cyclopentyl] hept-5-enoate
CAS Number	130209-82-4
PubChem CID	60798
DrugBank	APRD01065
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C26H40O5
Molar mass	432.593 g/mol

WikiDoc Resources for Latanoprost detailed information
Articles
Most recent articles on Latanoprost detailed information Most cited articles on Latanoprost detailed information Review articles on Latanoprost detailed information Articles on Latanoprost detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Latanoprost detailed information Images of Latanoprost detailed information Photos of Latanoprost detailed information Podcasts & MP3s on Latanoprost detailed information Videos on Latanoprost detailed information
Evidence Based Medicine
Cochrane Collaboration on Latanoprost detailed information Bandolier on Latanoprost detailed information TRIP on Latanoprost detailed information
Clinical Trials
Ongoing Trials on Latanoprost detailed information at Clinical Trials.gov Trial results on Latanoprost detailed information Clinical Trials on Latanoprost detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Latanoprost detailed information NICE Guidance on Latanoprost detailed information NHS PRODIGY Guidance FDA on Latanoprost detailed information CDC on Latanoprost detailed information
Books
Books on Latanoprost detailed information
News
Latanoprost detailed information in the news Be alerted to news on Latanoprost detailed information News trends on Latanoprost detailed information
Commentary
Blogs on Latanoprost detailed information
Definitions
Definitions of Latanoprost detailed information
Patient Resources / Community
Patient resources on Latanoprost detailed information Discussion groups on Latanoprost detailed information Patient Handouts on Latanoprost detailed information Directions to Hospitals Treating Latanoprost detailed information Risk calculators and risk factors for Latanoprost detailed information
Healthcare Provider Resources
Symptoms of Latanoprost detailed information Causes & Risk Factors for Latanoprost detailed information Diagnostic studies for Latanoprost detailed information Treatment of Latanoprost detailed information
Continuing Medical Education (CME)
CME Programs on Latanoprost detailed information
International
Latanoprost detailed information en Espanol Latanoprost detailed information en Francais
Business
Latanoprost detailed information in the Marketplace Patents on Latanoprost detailed information
Experimental / Informatics
List of terms related to Latanoprost detailed information

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Latanoprost (pronounced la-TA-noe-prost) ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.

It is also known by the brand name of Xalatan manufactured by Pfizer.

Side effects

Possible side effects:

• May cause reddening of the eyes (hyperemia)
• May cause blurred vision;
• May cause eyelid redness;
• May permanently darken eyelashes;
• May cause eye discomfort;
• May eventually cause permanent darkening of the iris to brown (heterochromia);
• May cause a temporary burning sensation during use.
• May cause thickening of the eyelashes.
• Rarely, herpes simplex keratitis.

External links

• Xalatan (manufacturer's website)
• Hara T (2001). "Increased iris pigmentation after use of latanoprost in Japanese brown eyes". Nippon Ganka Gakkai Zasshi. 105 (5): 314–21. PMID 11406947.

Template:Antiglaucoma preparations and miotics Template:Prostaglandins